Form SC 13D/A DEPOMED INC Filed by: Starboard Value LP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Depomed (DEPO) Will Not Pursue Proposed Reincorporation
April 14, 2016 4:58 PM EDTDepomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company") today announced that it will not pursue the proposed reincorporation of the Company from California to Delaware that was proposed in its preliminary proxy statement for its upcoming Annual Meeting of Shareholders (the "Annual Meeting").... More
Janney Notes Strong Nucynta Rx Trends for March; Affirms DepoMed (DEPO) at 'Buy'
April 13, 2016 7:57 AM EDTJanney affirms DepoMed (Nasdaq: DEPO) at Buy with a fair value estimate of $28 following a check on recent prescription trends
Analyst Ken Trbovich noted that Nucynta ER prescription growth was 23 percent for March, which came in ahead of the firm's expectations. The analyst... More
